Abstract: FR-PO837
Urinary Tract Infections in the First Year After Renal Transplantation in Current of Immunosuppression Setting: A 5-Year Retrospective Single-Centre Study
Session Information
- Transplantation: Clinical - Outcomes
November 04, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Transplantation
- 2002 Transplantation: Clinical
Authors
- Andrade, Jorge Carlos, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
- Andrade-Sierra, Jorge, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico
- Fuentes Lopez, Elsa Angelica, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
- Rojas-Campos, Enrique, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
- Martinez, Manuel, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
- Cerrillos, Jose Ignacio, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
- Evangelista-Carrillo, Luis Alberto, Instituto Mexicano del Seguro Social Delegacion Jalisco, Guadalajara, Jalisco, Mexico
Background
Urinary tract infection (UTI) is associated with development impaired allograft function. Our objective was assessing to UTI risk factors and its impact in the allograft function.
Methods
Retrospective Cohort from March-2014 to March-2019 included 1341 patients with kidney transplantation. All patients with development at least one UTI event during first year after transplantation were registered. Prophylaxis with TMP-SMX (160/800mg) was used for 3-6 months and the main immunosuppression scheme was based on TAC/MMF/PDN.
Results
The accumulated incidence of UTI was 41% and ESBL-producing Escherichia Coli was the most frequent agent causing. In a Logistic Regression analysis; risks factors were Anti-thymocyte globulin (ATG) (RR 1.5; 1.18-1.91; p=0.001), surgical complications (RR 2.4; 1.7-3.4; p=0.001), duration of bladder catheterization (RR 1.43; 1.09-1.9; p= 0.021), transplant number (RR 1.8; 1.09-3.0; p=0.001).
Conclusion
Despite the high incidence of UTI, there was no impact on graft function at 12 months post transplantation. Use of ATG and prolonged bladder catheterization are some of the risk factors.
| UTI=548 | No UTI=793 | P | |
| Age (years) | 32 ± 12 | 30 ± 10 | 0.003 |
| Male-gender n (%) | 344 (62.8) | 582 (73.4) | 0.001 |
| Induction, n (%) | |||
| ATG Basiliximab | 322 (59) 226 (41) | 507 (64) 286 (36) | 0.059 |
| Type of Donor (%) | |||
| Living donor Deseaced donor | 462 (84) 86 (15.7) | 690 (87) 103 (13) | NS |
| Transplant n (%) | |||
| First Second | 509 (93) 39 (7) | 758 (95.6) 35 (4.4) | NS |
| Double J stent n (%) | 125 (22.8) | 124 (15.6) | 0.006 |
| Bladder catheterization Time n (%) | |||
| < 5 6-7 7-14 >14 | 368 (67.2) 144 (26.3) 28 (5.0) 8 (1.5) | 624 (78.7) 142 (17.9) 24 (3.0) 3 (0.4) | 0.001 |
| CrS at 12-months (mg/dL) | 1.14 ± 0.58 | 1.23 ± 1.25 | NS |